 Gene Therapy Market Insights, Competitive Landscape, and Market Forecast - 2033
The gene therapy market is emerging as one of the most innovative and transformative segments within modern healthcare. By focusing on correcting or replacing defective genes, gene therapy provides... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe gene therapy market is emerging as one of the most innovative and transformative segments within modern healthcare. By focusing on correcting or replacing defective genes, gene therapy provides a breakthrough approach to treating complex and previously incurable diseases. With the growing burden of genetic disorders and chronic illnesses worldwide, the demand for advanced therapeutic solutions is accelerating. Continuous advancements in biotechnology, coupled with increasing clinical success rates, are positioning gene therapy as a cornerstone of next-generation medicine.Market Insights The global gene therapy market is expected to be valued at USD 9.3 billion in 2026 and is projected to reach USD 30.6 billion by 2033, expanding at a compound annual growth rate (CAGR) of 18.50% during the forecast period. This strong growth reflects rising adoption of gene-based treatments, increasing regulatory approvals, and growing investment in research and development. The market is witnessing significant progress in the development of innovative therapies targeting a wide range of diseases, including cancer, rare genetic conditions, and neurological disorders. Advancements in delivery systems and gene editing technologies are further strengthening the market outlook. Market Drivers The increasing prevalence of genetic and chronic diseases is a major factor driving the growth of the gene therapy market. Disorders such as cancer, muscular dystrophy, and inherited metabolic diseases are creating a strong demand for targeted and effective treatment options. Gene therapy offers a unique advantage by addressing the underlying genetic cause of diseases, rather than providing symptomatic relief. Technological advancements in genomics and molecular biology are also playing a crucial role in market expansion. The development of advanced gene editing tools and improved vector systems is enhancing the precision, efficiency, and safety of gene therapies. Additionally, rising investments from government agencies, private investors, and pharmaceutical companies are supporting extensive research activities. Favorable regulatory pathways for innovative therapies are further accelerating product approvals and commercialization. Business Opportunity The gene therapy market presents substantial opportunities for companies involved in biotechnology and pharmaceutical innovation. The focus on rare and orphan diseases is particularly promising, as these areas often have limited treatment options and high unmet medical needs. Companies developing breakthrough therapies in these segments can achieve significant market penetration and revenue growth. The expansion of manufacturing capabilities, particularly for viral and non-viral vectors, is another key opportunity area. Organizations investing in advanced production technologies can improve scalability and reduce costs, thereby enhancing competitiveness. Furthermore, emerging economies are becoming attractive markets due to increasing healthcare spending, improving infrastructure, and rising awareness about advanced treatment solutions. Strategic collaborations, licensing agreements, and partnerships are also enabling companies to accelerate product development and market entry. Region Analysis North America holds a dominant position in the gene therapy market, supported by strong research infrastructure, high healthcare expenditure, and the presence of leading industry players. The region benefits from a favorable regulatory environment and a high concentration of clinical trials, which facilitate rapid innovation and commercialization. Europe is also a significant contributor to market growth, driven by increasing investment in biotechnology and supportive government initiatives. The region’s well-established healthcare systems and growing focus on advanced therapies are encouraging the adoption of gene therapy solutions. Asia Pacific is expected to register the fastest growth over the forecast period. Countries such as China, Japan, and India are witnessing rising demand for advanced treatments due to increasing disease prevalence and expanding healthcare access. Government initiatives to promote biotechnology research and development are further boosting regional growth. Latin America and the Middle East & Africa are gradually emerging as promising markets, supported by improving healthcare infrastructure and growing awareness about gene therapy. Key Players • Merck KGaA • Novartis AG • AstraZeneca Plc. • BIOCAD • Crinetics Pharmaceuticals Inc. • EffRx Pharmaceuticals S.A. • Euroscreen S.A. • Vicore Pharma AB • Amgen • Bristol-Myers Squibb • Cell Genesys Inc. • Adaptimmune Therapeutics plc. • Achieve Life Science Inc. • BioCanCell Ltd. • Genelux Corporation • Advantagene Inc. • GenVec Inc • GlaxoSmithKline PLC Segmentation By Vector: • Grade Non-viral Vectors o Oligonucleotides o Other Non-viral Vectors • Viral Vectors o Retro Viral Vectors o Adeno-associated Virus Vectors o Others Viral Vectors By Indication: • Neurological Diseases • Cancer • DMD (Duchenne Muscular Dystrophy) • Hepatological Diseases • Other Indications By Delivery Method: • In Vivo • Ex Vivo By Sales Channel: • Offline Sales Channel o Supermarkets/Hypermarkets o Departmental Stores o Convenience Store o Other Sales Channel • Online Sales Channel o Company Website o E-commerce Platform By Geographic Coverage: • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Gene Therapy Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Gene Therapy Market Outlook, 2020 - 2033 3.1. Global Gene Therapy Market Outlook, by Vector, Value (US$ Bn), 2020-2033 3.1.1. Grade Non-viral Vectors 3.1.1.1. Oligonucleotides 3.1.1.2. Other Non-viral Vectors 3.1.2. Viral Vectors 3.1.2.1. Retro Viral Vectors 3.1.2.2. Adeno-associated Virus Vectors 3.1.2.3. Others Viral Vectors 3.2. Global Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2020-2033 3.2.1. Offline Sales Channel 3.2.1.1. Supermarkets/Hypermarkets 3.2.1.2. Departmental Stores 3.2.1.3. Convenience Store 3.2.1.4. Other Sales Channel 3.2.2. Online Sales Channel 3.2.2.1. Company Website 3.2.2.2. E-commerce Platform 3.2.3. Hepatological Diseases 3.2.4. Other Indications 3.3. Global Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2020-2033 3.3.1. In Vivo 3.3.2. Ex Vivo 3.4. Global Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033 3.4.1. Neurological Diseases 3.4.2. Cancer 3.4.3. DMD (Duchenne Muscular Dystrophy) 3.5. Global Gene Therapy Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Latin America 3.5.5. Middle East & Africa 4. North America Gene Therapy Market Outlook, 2020 - 2033 4.1. North America Gene Therapy Market Outlook, by Vector, Value (US$ Bn), 2020-2033 4.1.1. Grade Non-viral Vectors 4.1.1.1. Oligonucleotides 4.1.1.2. Other Non-viral Vectors 4.1.2. Viral Vectors 4.1.2.1. Retro Viral Vectors 4.1.2.2. Adeno-associated Virus Vectors 4.1.2.3. Others Viral Vectors 4.2. North America Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2020-2033 4.2.1. Offline Sales Channel 4.2.1.1. Supermarkets/Hypermarkets 4.2.1.2. Departmental Stores 4.2.1.3. Convenience Store 4.2.1.4. Other Sales Channel 4.2.2. Online Sales Channel 4.2.2.1. Company Website 4.2.2.2. E-commerce Platform 4.2.3. Hepatological Diseases 4.2.4. Other Indications 4.3. North America Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2020-2033 4.3.1. In Vivo 4.3.2. Ex Vivo 4.4. North America Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033 4.4.1. Neurological Diseases 4.4.2. Cancer 4.4.3. DMD (Duchenne Muscular Dystrophy) 4.5. North America Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.5.1. U.S. Gene Therapy Market Outlook, by Vector, 2020-2033 4.5.2. U.S. Gene Therapy Market Outlook, by Sales Channel, 2020-2033 4.5.3. U.S. Gene Therapy Market Outlook, by Delivery Method, 2020-2033 4.5.4. U.S. Gene Therapy Market Outlook, by Indication, 2020-2033 4.5.5. Canada Gene Therapy Market Outlook, by Vector, 2020-2033 4.5.6. Canada Gene Therapy Market Outlook, by Sales Channel, 2020-2033 4.5.7. Canada Gene Therapy Market Outlook, by Delivery Method, 2020-2033 4.5.8. Canada Gene Therapy Market Outlook, by Indication, 2020-2033 4.6. BPS Analysis/Market Attractiveness Analysis 5. Europe Gene Therapy Market Outlook, 2020 - 2033 5.1. Europe Gene Therapy Market Outlook, by Vector, Value (US$ Bn), 2020-2033 5.1.1. Grade Non-viral Vectors 5.1.1.1. Oligonucleotides 5.1.1.2. Other Non-viral Vectors 5.1.2. Viral Vectors 5.1.2.1. Retro Viral Vectors 5.1.2.2. Adeno-associated Virus Vectors 5.1.2.3. Others Viral Vectors 5.2. Europe Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2020-2033 5.2.1. Offline Sales Channel 5.2.1.1. Supermarkets/Hypermarkets 5.2.1.2. Departmental Stores 5.2.1.3. Convenience Store 5.2.1.4. Other Sales Channel 5.2.2. Online Sales Channel 5.2.2.1. Company Website 5.2.2.2. E-commerce Platform 5.2.3. Hepatological Diseases 5.2.4. Other Indications 5.3. Europe Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2020-2033 5.3.1. In Vivo 5.3.2. Ex Vivo 5.4. Europe Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033 5.4.1. Neurological Diseases 5.4.2. Cancer 5.4.3. DMD (Duchenne Muscular Dystrophy) 5.5. Europe Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.5.1. Germany Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.2. Germany Gene Therapy Market Outlook, by Sales Channel, 2020-2033 5.5.3. Germany Gene Therapy Market Outlook, by Delivery Method, 2020-2033 5.5.4. Germany Gene Therapy Market Outlook, by Indication, 2020-2033 5.5.5. Italy Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.6. Italy Gene Therapy Market Outlook, by Sales Channel, 2020-2033 5.5.7. Italy Gene Therapy Market Outlook, by Delivery Method, 2020-2033 5.5.8. Italy Gene Therapy Market Outlook, by Indication, 2020-2033 5.5.9. France Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.10. France Gene Therapy Market Outlook, by Sales Channel, 2020-2033 5.5.11. France Gene Therapy Market Outlook, by Delivery Method, 2020-2033 5.5.12. France Gene Therapy Market Outlook, by Indication, 2020-2033 5.5.13. U.K. Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.14. U.K. Gene Therapy Market Outlook, by Sales Channel, 2020-2033 5.5.15. U.K. Gene Therapy Market Outlook, by Delivery Method, 2020-2033 5.5.16. U.K. Gene Therapy Market Outlook, by Indication, 2020-2033 5.5.17. Spain Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.18. Spain Gene Therapy Market Outlook, by Sales Channel, 2020-2033 5.5.19. Spain Gene Therapy Market Outlook, by Delivery Method, 2020-2033 5.5.20. Spain Gene Therapy Market Outlook, by Indication, 2020-2033 5.5.21. Russia Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.22. Russia Gene Therapy Market Outlook, by Sales Channel, 2020-2033 5.5.23. Russia Gene Therapy Market Outlook, by Delivery Method, 2020-2033 5.5.24. Russia Gene Therapy Market Outlook, by Indication, 2020-2033 5.5.25. Rest of Europe Gene Therapy Market Outlook, by Vector, 2020-2033 5.5.26. Rest of Europe Gene Therapy Market Outlook, by Sales Channel, 2020-2033 5.5.27. Rest of Europe Gene Therapy Market Outlook, by Delivery Method, 2020-2033 5.5.28. Rest of Europe Gene Therapy Market Outlook, by Indication, 2020-2033 5.6. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Gene Therapy Market Outlook, 2020 - 2033 6.1. Asia Pacific Gene Therapy Market Outlook, by Vector, Value (US$ Bn), 2020-2033 6.1.1. Grade Non-viral Vectors 6.1.1.1. Oligonucleotides 6.1.1.2. Other Non-viral Vectors 6.1.2. Viral Vectors 6.1.2.1. Retro Viral Vectors 6.1.2.2. Adeno-associated Virus Vectors 6.1.2.3. Others Viral Vectors 6.2. Asia Pacific Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2020-2033 6.2.1. Offline Sales Channel 6.2.1.1. Supermarkets/Hypermarkets 6.2.1.2. Departmental Stores 6.2.1.3. Convenience Store 6.2.1.4. Other Sales Channel 6.2.2. Online Sales Channel 6.2.2.1. Company Website 6.2.2.2. E-commerce Platform 6.2.3. Hepatological Diseases 6.2.4. Other Indications 6.3. Asia Pacific Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2020-2033 6.3.1. In Vivo 6.3.2. Ex Vivo 6.4. Asia Pacific Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033 6.4.1. Neurological Diseases 6.4.2. Cancer 6.4.3. DMD (Duchenne Muscular Dystrophy) 6.5. Asia Pacific Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.5.1. China Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.2. China Gene Therapy Market Outlook, by Sales Channel, 2020-2033 6.5.3. China Gene Therapy Market Outlook, by Delivery Method, 2020-2033 6.5.4. China Gene Therapy Market Outlook, by Indication, 2020-2033 6.5.5. Japan Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.6. Japan Gene Therapy Market Outlook, by Sales Channel, 2020-2033 6.5.7. Japan Gene Therapy Market Outlook, by Delivery Method, 2020-2033 6.5.8. Japan Gene Therapy Market Outlook, by Indication, 2020-2033 6.5.9. South Korea Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.10. South Korea Gene Therapy Market Outlook, by Sales Channel, 2020-2033 6.5.11. South Korea Gene Therapy Market Outlook, by Delivery Method, 2020-2033 6.5.12. South Korea Gene Therapy Market Outlook, by Indication, 2020-2033 6.5.13. India Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.14. India Gene Therapy Market Outlook, by Sales Channel, 2020-2033 6.5.15. India Gene Therapy Market Outlook, by Delivery Method, 2020-2033 6.5.16. India Gene Therapy Market Outlook, by Indication, 2020-2033 6.5.17. Southeast Asia Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.18. Southeast Asia Gene Therapy Market Outlook, by Sales Channel, 2020-2033 6.5.19. Southeast Asia Gene Therapy Market Outlook, by Delivery Method, 2020-2033 6.5.20. Southeast Asia Gene Therapy Market Outlook, by Indication, 2020-2033 6.5.21. Rest of SAO Gene Therapy Market Outlook, by Vector, 2020-2033 6.5.22. Rest of SAO Gene Therapy Market Outlook, by Sales Channel, 2020-2033 6.5.23. Rest of SAO Gene Therapy Market Outlook, by Delivery Method, 2020-2033 6.5.24. Rest of SAO Gene Therapy Market Outlook, by Indication, 2020-2033 6.6. BPS Analysis/Market Attractiveness Analysis 7. Latin America Gene Therapy Market Outlook, 2020 - 2033 7.1. Latin America Gene Therapy Market Outlook, by Vector, Value (US$ Bn), 2020-2033 7.1.1. Grade Non-viral Vectors 7.1.1.1. Oligonucleotides 7.1.1.2. Other Non-viral Vectors 7.1.2. Viral Vectors 7.1.2.1. Retro Viral Vectors 7.1.2.2. Adeno-associated Virus Vectors 7.1.2.3. Others Viral Vectors 7.2. Latin America Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2020-2033 7.2.1. Offline Sales Channel 7.2.1.1. Supermarkets/Hypermarkets 7.2.1.2. Departmental Stores 7.2.1.3. Convenience Store 7.2.1.4. Other Sales Channel 7.2.2. Online Sales Channel 7.2.2.1. Company Website 7.2.2.2. E-commerce Platform 7.2.3. Hepatological Diseases 7.2.4. Other Indications 7.3. Latin America Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2020-2033 7.3.1. In Vivo 7.3.2. Ex Vivo 7.4. Latin America Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033 7.4.1. Neurological Diseases 7.4.2. Cancer 7.4.3. DMD (Duchenne Muscular Dystrophy) 7.5. Latin America Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.5.1. Brazil Gene Therapy Market Outlook, by Vector, 2020-2033 7.5.2. Brazil Gene Therapy Market Outlook, by Sales Channel, 2020-2033 7.5.3. Brazil Gene Therapy Market Outlook, by Delivery Method, 2020-2033 7.5.4. Brazil Gene Therapy Market Outlook, by Indication, 2020-2033 7.5.5. Mexico Gene Therapy Market Outlook, by Vector, 2020-2033 7.5.6. Mexico Gene Therapy Market Outlook, by Sales Channel, 2020-2033 7.5.7. Mexico Gene Therapy Market Outlook, by Delivery Method, 2020-2033 7.5.8. Mexico Gene Therapy Market Outlook, by Indication, 2020-2033 7.5.9. Argentina Gene Therapy Market Outlook, by Vector, 2020-2033 7.5.10. Argentina Gene Therapy Market Outlook, by Sales Channel, 2020-2033 7.5.11. Argentina Gene Therapy Market Outlook, by Delivery Method, 2020-2033 7.5.12. Argentina Gene Therapy Market Outlook, by Indication, 2020-2033 7.5.13. Rest of LATAM Gene Therapy Market Outlook, by Vector, 2020-2033 7.5.14. Rest of LATAM Gene Therapy Market Outlook, by Sales Channel, 2020-2033 7.5.15. Rest of LATAM Gene Therapy Market Outlook, by Delivery Method, 2020-2033 7.5.16. Rest of LATAM Gene Therapy Market Outlook, by Indication, 2020-2033 7.6. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Gene Therapy Market Outlook, 2020 - 2033 8.1. Middle East & Africa Gene Therapy Market Outlook, by Vector, Value (US$ Bn), 2020-2033 8.1.1. Grade Non-viral Vectors 8.1.1.1. Oligonucleotides 8.1.1.2. Other Non-viral Vectors 8.1.2. Viral Vectors 8.1.2.1. Retro Viral Vectors 8.1.2.2. Adeno-associated Virus Vectors 8.1.2.3. Others Viral Vectors 8.2. Middle East & Africa Gene Therapy Market Outlook, by Sales Channel, Value (US$ Bn), 2020-2033 8.2.1. Offline Sales Channel 8.2.1.1. Supermarkets/Hypermarkets 8.2.1.2. Departmental Stores 8.2.1.3. Convenience Store 8.2.1.4. Other Sales Channel 8.2.2. Online Sales Channel 8.2.2.1. Company Website 8.2.2.2. E-commerce Platform 8.2.3. Hepatological Diseases 8.2.4. Other Indications 8.3. Middle East & Africa Gene Therapy Market Outlook, by Delivery Method, Value (US$ Bn), 2020-2033 8.3.1. In Vivo 8.3.2. Ex Vivo 8.4. Middle East & Africa Gene Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033 8.4.1. Neurological Diseases 8.4.2. Cancer 8.4.3. DMD (Duchenne Muscular Dystrophy) 8.5. Middle East & Africa Gene Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.5.1. GCC Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.2. GCC Gene Therapy Market Outlook, by Sales Channel, 2020-2033 8.5.3. GCC Gene Therapy Market Outlook, by Delivery Method, 2020-2033 8.5.4. GCC Gene Therapy Market Outlook, by Indication, 2020-2033 8.5.5. South Africa Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.6. South Africa Gene Therapy Market Outlook, by Sales Channel, 2020-2033 8.5.7. South Africa Gene Therapy Market Outlook, by Delivery Method, 2020-2033 8.5.8. South Africa Gene Therapy Market Outlook, by Indication, 2020-2033 8.5.9. Egypt Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.10. Egypt Gene Therapy Market Outlook, by Sales Channel, 2020-2033 8.5.11. Egypt Gene Therapy Market Outlook, by Delivery Method, 2020-2033 8.5.12. Egypt Gene Therapy Market Outlook, by Indication, 2020-2033 8.5.13. Nigeria Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.14. Nigeria Gene Therapy Market Outlook, by Sales Channel, 2020-2033 8.5.15. Nigeria Gene Therapy Market Outlook, by Delivery Method, 2020-2033 8.5.16. Nigeria Gene Therapy Market Outlook, by Indication, 2020-2033 8.5.17. Rest of Middle East Gene Therapy Market Outlook, by Vector, 2020-2033 8.5.18. Rest of Middle East Gene Therapy Market Outlook, by Sales Channel, 2020-2033 8.5.19. Rest of Middle East Gene Therapy Market Outlook, by Delivery Method, 2020-2033 8.5.20. Rest of Middle East Gene Therapy Market Outlook, by Indication, 2020-2033 8.6. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Merck KGaA 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Novartis AG 9.4.3. AstraZeneca Plc. 9.4.4. BIOCAD 9.4.5. Crinetics Pharmaceuticals Inc. 9.4.6. EffRx Pharmaceuticals S.A. 9.4.7. Euroscreen S.A. 9.4.8. Vicore Pharma AB 9.4.9. Amgen 9.4.10. Bristol-Myers Squibb 9.4.11. Cell Genesys Inc. 9.4.12. Adaptimmune Therapeutics plc. 9.4.13. Achieve Life Science Inc. 9.4.14. BioCanCell Ltd. 9.4.15. Genelux Corporation 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（環境・エネルギー）の最新刊レポート
Fairfield Market Research社の エネルギー・天然資源分野 での最新刊レポート
本レポートと同じKEY WORD（gene）の最新刊レポートよくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
